ALC Stock Forecast & Price Target

Alcon is well positioned as a pure-play leader in ophthalmic medical devices, with a diversified mix of vision care and surgical products that is still benefiting from new launches rather than relying on a mature portfolio alone. The company delivered about 7% xFx growth in 2Q26, with core EPS of $0.84 and gross and operating margins beating expectations by 340 bps and 190 bps, while FY26 guidance implies 5%-7% xFx revenue growth and core operating margins of 20.7%-21.7%. Its appeal is further supported by record contact lens share, strong adoption of PanOptix Pro, improving Unity equipment placements, and expanding coverage for Tryptyr and Valeda, which together suggest sustained top-line growth, operating leverage, and share buybacks.

Alcon is facing a negative setup because FY26 growth guidance of 5%-7% xFx, or about $10.927B to $11.134B of sales, still assumes only 3%-4% global eye care market growth while weaker-than-expected uptake of new products and heavier competition keep growth below the 6%-8% range. Tariffs remain a material drag, with a net FY26 headwind of roughly $40M-$90M or $100M-$150M, pressuring COGS even after mitigation and partial refunds, while a $402M PowerVision write-off underscores execution risk. With core operating margins only expected in the low-20s and not expanding meaningfully over a longer period, the stock appears likely to remain range-bound amid slower margin improvement and end-market softness.